CD40LG and episodic ataxia type 2: This study therefore, aimed at determining anti-Aspergillus-specific IgG/IgM serostatus in patients with moderate and severe COVID – 19 in Uganda to guide future studies and clinical care of these patients who are at risk of CAPA.